文献速递系统性红斑狼疮

Pim-1作为狼疮肾炎治疗靶点的研究

Pim-1 as a Therapeutic Target in Lupus Nephritis.
PubMed 文献 · Arthritis Rheumatol · 2019-07-02

该研究在狼疮倾向(NZB×NZW)F1小鼠、SLE患者外周血单个核细胞及LN患者肾小球中分析Pim-1表达,并用Pim-1抑制剂AZD1208干预小鼠,发现Pim-1在LN中上调,抑制Pim-1可减轻蛋白尿、肾小球肾炎及免疫复合物沉积,机制涉及NFATc1/NLRP3通路。

要点

  • Pim-1在狼疮倾向小鼠肾脏及SLE患者PBMC和LN肾小球中表达上调。
  • Pim-1抑制剂AZD1208减轻小鼠蛋白尿、肾小球肾炎和抗dsDNA抗体水平。
  • Pim-1通过NFATc1/NLRP3通路调控足细胞炎症,靶向该通路可能有治疗潜力。

核心结论

  • Pim-1是狼疮肾炎发病的关键调节因子,靶向Pim-1/NFATc1/NLRP3通路可能对人类LN具有治疗潜力。

研究设计与样本

  • 研究分析狼疮倾向(NZB×NZW)F1小鼠(n=6)、SLE患者PBMC(n=10)和LN患者肾小球(n=8)中Pim-1表达。
  • 在(NZB×NZW)F1小鼠(每组n=10)中评估Pim-1抑制剂AZD1208的治疗效果,并在MRL/lpr小鼠(每组n=10)中验证。
  • 体外分析抗dsDNA抗体阳性血清诱导足细胞Pim-1表达后的机制。

主要发现

  • 与对照相比,患病(NZB×NZW)F1小鼠肾脏裂解液、SLE患者PBMC和LN患者肾活检组织中Pim-1表达上调(各P<0.05)。
  • AZD1208降低患病(NZB×NZW)F1小鼠蛋白尿严重程度、肾小球肾炎、肾脏免疫复合物沉积和血清抗dsDNA抗体水平,并抑制NFATc1表达和NLRP3炎症小体活化(各P<0.05 vs 对照)。
  • 在抗dsDNA阳性血清存在下,Pim-1 siRNA敲低抑制小鼠和人类足细胞中NFATc1和NLRP3炎症小体信号(各P<0.05 vs 对照siRNA)。
  • Pim-1通过细胞内Ca2+调控NLRP3炎症小体活化(P<0.05 vs 正常对照)。
  • Pim-1阻断的治疗效果在MRL/lpr小鼠中重复验证。

临床怎么用

  • Pim-1表达上调见于SLE患者PBMC和LN肾活检组织,可能作为LN的潜在生物标志物。
  • Pim-1抑制剂AZD1208在狼疮小鼠模型中减轻肾脏损伤和自身抗体水平,提示Pim-1/NFATc1/NLRP3通路是潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lupus nephritis (LN) is a major determinant of morbidity and mortality in systemic lupus erythematosus (SLE). Pim-1 regulates lymphocyte proliferation and activation. The role of Pim-1 in autoimmune disease remains unclear. This study was undertaken to test the hypothesis that inhibition of Pim-1 would have therapeutic potential in patients with LN. METHODS: Pim-1 expression was analyzed in lupus-prone (NZB × NZW)F1 mice (n = 6), human peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 10), and glomeruli from patients with LN (n = 8). The therapeutic effect of the Pim-1 inhibitor AZD1208 was assessed in the same murine lupus model (n = 10 mice per group). In vitro analysis was conducted to explore the mechanisms of action of Pim-1 in mouse and human podocytes after Pim-1 expression had been induced by anti-double-stranded DNA (anti-dsDNA) antibody-positive serum. Finally, MRL/lpr mice were used to confirm the therapeutic effects of Pim-1 inhibition in vivo (n = 10 mice per group). RESULTS: Up-regulation of Pim-1 was seen in renal lysates from diseased (NZB × NZW)F1 mice and in PBMCs from patients with SLE and renal biopsy tissue from patients with LN, relative to their control counterparts (each P < 0.05). The Pim-1 inhibitor AZD1208 reduced the severity of proteinuria, glomerulonephritis, renal immune complex deposits, and serum anti-dsDNA antibody levels, concomitant with the suppression of NFATc1 expression and NLRP3 inflammasome activation, in diseased (NZB × NZW)F1 mice (each P < 0.05 versus controls). Moreover, in mouse and human podocytes, Pim-1 knockdown with targeted small interfering RNA (siRNA) suppressed NFATc1 and NLRP3 inflammasome signaling in the presence of anti-dsDNA-positive serum (each P < 0.05 versus control siRNA). Mechanistically, Pim-1 modulated NLRP3 inflammasome activation through intracellular Ca2+ (P < 0.05 versus normal controls). The therapeutic effect of Pim-1 blockade was replicated in MRL/lpr mice. CONCLUSION: These data identify Pim-1 as a critical regulator of LN pathogenesis in patients with SLE. Targeting of the Pim-1/NFATc1/NLRP3 pathway might therefore have therapeutic potential in human LN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fu R, Xia Y, Li M, et al. Pim-1 as a Therapeutic Target in Lupus Nephritis. Arthritis Rheumatol. 2019. PMID: 30791224. doi:10.1002/art.40863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。